多西紫杉醇联合替吉奥治疗蒽环类耐药晚期三阴乳腺癌疗效观察  

Docetaxel Combined with S-1 in the Treatment of Anthracycline-resistant Advanced Triple-negtive Breast Cancer

作　　者：谢彦[1] 陈冬波[1] 谢晓东[2] 

机构地区：[1]徐州医学院第二附属医院肿瘤内科,江苏徐州221000 [2]徐州市肿瘤医院肿瘤内科,江苏徐州221005

出　　处：《肿瘤基础与临床》2013年第4期298-300,共3页journal of basic and clinical oncology

摘　　要：目的观察多西紫杉醇联合替吉奥治疗蒽环类耐药晚期三阴乳腺癌(TNBC)的临床疗效和毒副反应。方法采用多西紫杉醇联合替吉奥治疗46例蒽环类耐药的晚期TNBC患者,3周为1周期,治疗2周期后评价疗效及毒副反应。结果 46例患者中,CR 1例,PR 15例,SD 18例,PD 12例,有效率34.8%,疾病控制率73.9%。主要毒副反应为骨髓抑制和胃肠道反应,无化疗相关死亡患者。结论多西紫杉醇联合替吉奥治疗蒽环类耐药晚期TNBC有效,毒副反应轻,患者耐受性好。Objective To observe the efficacy and toxicities of docetaxel combined with S-1 in the treatment of anthracycline-resistant advanced triple-negative breast cancer （TNBC）. Methods Forty-six patients with anthracycline-resistant advanced TNBC were treated with docetaxel and S-l, every 3 weeks were 1 cycle,the efficacy and toxicities were evaluated after 2 cycles. Results Of the 46 patients, CR was observed in the 1 case,PR in the 15 cases, SD in the 18 cases, PD in the 12 cases, the response rate was 34.8 %, the disease control rate was 73.9%. The main toxicities were bone marrow suppression and gastrointestinal reaction, no chemotherapy-related death was observed. Conclusion Docetaxel combined with S-1 is effective and safe for anthracycline-resistant advanced TNBC.

关 键 词：多西紫杉醇 替吉奥 蒽环类药物 晚期三阴乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]